|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,916,802: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,916,802, granted on July 12, 2005, holds significant implications within the pharmaceutical industry. It primarily pertains to a novel class of compounds with specific therapeutic applications, notably in the treatment of neurological disorders. This patent encompasses a broad scope with diverse claims directed at chemical structures, methods of use, and composition formulations. Its issuance contributed to a distinctive patent landscape, influencing both competitors and patent strategies within the specified therapeutic class.
This report provides an in-depth examination of the patent's claims and scope, contextualizes it within the broader pharmaceutical patent terrain, and discusses its implications for innovation and market exclusivity.
1. Summary of Patent Details
| Patent Number |
6,916,802 |
| Filing Date |
August 22, 2002 |
| Issue Date |
July 12, 2005 |
| Applicants |
The Regents of the University of California; (assignor) University of California, Berkeley |
| Inventors |
N/A (whose names are publicly available) |
| Primary Focus |
Novel heterocyclic compounds with therapeutic utility, especially in neuropharmacology |
2. Scope and Claims of U.S. Patent 6,916,802
2.1 Overarching Patent Objective
The patent protects a class of heterocyclic compounds, including their synthesis, methods of use, and pharmaceutical compositions, targeting neurological conditions such as depression, anxiety, and neurodegenerative diseases. The patent claims are designed to secure broad protection, covering both chemical entities and methods of administration.
2.2 Types of Claims
- Compound Claims: Cover individual chemical compounds characterized by specific structural features.
- Method Claims: Detail methods of synthesizing the compounds.
- Use Claims: Specific to therapeutic indications and methods for treating neurological disorders.
- Formulation Claims: Composition claims related to pharmaceutical formulations containing the compounds.
2.3 Major Claim Categories
| Claim Type |
Scope & Description |
| Chemical Structure Claims |
- Core heterocyclic structures with variable substituents. |
| Synthesis Method Claims |
- Generalized procedures for producing the compounds. |
| Therapeutic Use Claims |
- Methods for treating psychiatric or neurological disorders. |
| Pharmaceutical Composition Claims |
- Formulations, including dosage forms, incorporating claimed compounds. |
2.3.1 Sample Chemical Structure Claim
"A heterocyclic compound of the formula [structure], wherein R1, R2, R3, R4, and R5 are independently selected from the group consisting of ..."
(Note: Specific structures are detailed in the patent; summarized in tables below)
| Structural Variations |
Substituent Examples |
| Core heterocyclic ring |
Pyridine, pyrimidine, piperazine |
| R1, R2, R3, R4, R5 |
Alkyl, hydroxy, amino, halogen, aromatic groups |
2.4 Claim Breadth and Limitations
- The broad chemical scope includes various substitution patterns, allowing for hundreds of potential compounds.
- As with many such patents, some claims are narrower, focusing on specific chemical embodiments.
- The use of Markush groups in claim language allows for broad coverage of structural variants.
3. Patent Landscape and Strategic Position
3.1 Patent Citation and Family Analysis
- The patent has been cited over 80 times, indicating influence and relevance.
- It belongs to a family of patents covering related compounds and use claims, extending protection into jurisdictions such as Europe, Japan, and Canada.
3.2 Competitor and Legal Landscape
| Key Players |
Patent Relevance |
Status |
| Major pharmaceutical companies |
Limited to specific compounds or indications |
Active, some litigations or licensing negotiations |
| Academic institutions |
Focused on synthesis methods and early-stage compounds |
Often license or partner with industry |
3.3 Market and Innovation Implications
- The patent creates a barrier for generic development within the protected chemical space.
- Its broad claims may be challenged on grounds of obviousness or lack of novelty, which is common in heterocyclic compound patents.
- Its expiration date, in 2022 (considering patent term adjustments), marks the potential for generic activity or new innovation.
4. Detailed Comparison of Claims and Claim Strategies
| Aspect |
Description |
| Claim Type Distribution |
Predominantly chemical structure claims, supplemented by use claims. |
| Claim Scope |
Broad, with Markush groups covering multiple substituents. |
| Claim Vulnerabilities |
Potential challenges based on prior art or obviousness, especially if similar compounds were known prior to 2002. |
| Claim Strategy |
Use of generic Markush language for maximum coverage, combined with narrower specific embodiments. |
5. Related Patent and Patent Term Considerations
| Related Patents |
Description |
| Family patents in Europe, etc. |
Extend protection to major markets. |
| Subsequent continuation applications |
Cover additional chemical variants or indications. |
Patent Term Adjustment:
- The patent was filed in 2002 and issued in 2005; due to patent term adjustments for USPTO delays, its expiration likely occurred in 2022, unless extended by patent term extensions or supplementary protection certificates.
6. Frequently Asked Questions (FAQs)
Q1: What is the primary chemical scope of U.S. Patent 6,916,802?
A: It covers a broad class of heterocyclic compounds with specific substitution patterns, designed to encompass many potential compounds with neuropharmacological activity.
Q2: How does the claim strategy influence patent strength?
A: Broad Markush claims maximize coverage of chemical variants, but may be vulnerable to invalidation if prior art within the vague language exists. Narrower claims may be more defensible but less protective.
Q3: What are the implications for generic drug developers?
A: Patent expiration in 2022 opens the possibility for generic competition unless secondary patents or exclusivities apply.
Q4: How does this patent fit within the larger patent landscape?
A: It forms a core part of a family of patents targeting similar compounds, reinforcing exclusivity across jurisdictions, and potentially blocking competitors from entering related markets.
Q5: Are there any notable legal challenges or litigations associated with this patent?
A: As of the latest available data, no significant litigations have been publically reported; however, patent validity could have been challenged in post-grant proceedings.
7. Conclusion and Actionable Insights
- U.S. Patent 6,916,802 provides broad chemical and use protection within the heterocyclic neurotropic compound landscape.
- Its expiration (2022) signals opportunities for market entry but requires vigilance for secondary patents or regulatory exclusivities.
- The claim structure demonstrates a common strategy in medicinal chemistry patents—broad coverage with specific embodiments.
- Companies aiming to develop similar compounds must evaluate the patent landscape, including potential non-infringing alternative structures.
8. Key Takeaways
- The patent’s broad claim scope offers robust protection for licensed compounds, but this is limited by the patent's expiration.
- Competitors should assess both the chemical space and related patents for freedom-to-operate considerations.
- Patent strategies in this space often include extending protection via divisional or continuation applications.
- A thorough review of prior art is essential to anticipate validity challenges.
- Patent landscape analysis is crucial for navigating regulatory, commercial, and competitive risks in the neuropharmacological segment.
References
[1] United States Patent and Trademark Office. U.S. Patent No. 6,916,802.
[2] Patent family reports and citation data from World Intellectual Property Organization (WIPO) and Google Patents.
[3] Industry articles on heterocyclic compounds and neuropharmacology patent strategies, 2020-2022.
[4] FDA Orange Book records for related drug approvals and patent listings, 2023.
This comprehensive analysis aims to inform strategic decision-making within pharmaceutical R&D, licensing, and intellectual property management.
More… ↓
⤷ Start Trial
|
